Reports Q4 revenue $7.18M, consensus $6.98M. "The growth of our commercial organization combined with the success of our marketing efforts have continued to deliver increased adoption of Barostim, resulting in the more than doubling of our U.S. heart failure business as compared to 2021. Importantly, patients continued to report a positive and meaningful impact from the therapy," said Nadim Yared, President and CEO of CVRx. "This has been a fantastic final quarter to a strong year and we are very excited to see these trends continue heading into 2023 as we work to promote further awareness among physicians, hospitals and patients in order to accelerate the adoption of Barostim."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVRX:
- CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
- CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023
- CVRx price target raised to $18.50 from $14 at Piper Sandler
- CVRx sees FY23 revenue $35M-$38M, consensus $38M
- CVRx sees FY22 revenue $22.3M-$22.4M, consensus $22.16M
